LOC152742 Inhibitors
LOC152742 inhibitors encompass a diverse array of chemical compounds that directly or indirectly lead to the reduced functional activity of LOC152742. Compounds such as Wortmannin and LY294002 target the PI3K/AKT signaling pathway, which is a critical regulatory axis for numerous cellular functions, potentially including those involving LOC152742. By inhibiting PI3Ks, these chemicals prevent the activation of AKT, leading to a downstream reduction in the phosphorylation and activity of relevant substrates and effectors. Similarly, Lapatinib's ability to obstruct EGFR and HER2 receptors attenuates the PI3K/AKT and RAS/MEK/ERK pathways, which may intersect with LOC152742's regulatory mechanisms. U0126, inhibiting MEK1/2, and SB203580, targeting p38 MAPK, further exemplify the breadth of strategies to dampen pathways that could influence the activity or expression of LOC152742, by reducing the activation of transcription factors that could govern its expression.
Rapamycin and Palbociclib offer distinct yet converging approaches to impeding LOC152742 function by directly inhibiting mTOR and CDK4/6, respectively, thus impacting protein synthesis and cell cycle progression, which could, in turn, affect LOC152742's role in these processes. The inhibition of mTOR by Rapamycin may exert a negative consequence on downstream proteins linked to cell growth and survival, potentially including LOC152742. Additionally, the proteasome inhibitor Bortezomib disrupts protein degradation pathways, which may lead to altered stability or function of LOC152742. Thapsigargin's interference with calcium homeostasis could similarly affect LOC152742 by altering calcium-dependent signaling pathways. In tandem, these inhibitors signify a multifaceted pharmacological approach to diminishing the biological activities associated with LOC152742. Each inhibitor, through its unique mode of action, converges on the common outcome of dampening the functional activity of LOC152742, whether it be through disarming key signaling nodes, impeding cell cycle regulators, or perturbing the proteostasis network, thereby providing a comprehensive toolkit for the potential modulation of LOC152742's cellular roles.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3Ks, it can prevent the activation of the AKT signaling pathway, which may be crucial for the function of LOC152742, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor and works similarly to Wortmannin by blocking the PI3K/AKT pathway. Inhibition of this pathway can lead to reduced phosphorylation and activity of downstream targets, potentially including LOC152742. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is an EGFR and HER2 inhibitor. By blocking these receptors, downstream signaling pathways like PI3K/AKT and RAS/MEK/ERK, which might be involved in the regulation of LOC152742, can be inhibited. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. Inhibition of this pathway can lead to decreased activation of transcription factors that may regulate LOC152742 expression or activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits the mTOR pathway, which can control protein synthesis and cell growth. By inhibiting mTOR, the activity of downstream proteins that rely on mTOR signaling, possibly including LOC152742, is decreased. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. The p38 MAPK pathway is involved in stress responses and inflammation. Inhibition of this pathway could affect the stability or activity of proteins involved in these processes, potentially including LOC152742. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling cascade. By inhibiting JNK, transcription factors that are downstream targets and may regulate the expression or activity of LOC152742 are affected. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, specifically targeting BCR-ABL, c-KIT, and PDGFR. By inhibiting these kinases, it indirectly affects various signaling pathways including those that might control the expression or function of LOC152742. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR. Its broad activity on these kinases can lead to the downregulation of signaling pathways potentially involved in the function of LOC152742. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor, leading to a halt in cell cycle progression. This could decrease the expression of proteins required for cell cycle progression, which may include LOC152742. | ||||||